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Objectives: To study hormonal receptor status (HRS) of malignant ovarian tumors (MOT) and determine its clinical significance. 
Patients and Methods: Retrospective analysis of case histories of 284 patients with MOT of different genesis of I–IV stages was 
carried out; immunohistochemical study of paraffin-embedded tissues. The HRS for serous, mucinous ovarian cancer (OC) and 
sex cord-stromal tumors (SCST) was studied. The phenotype of tumors by HRS in patients with serous OC was determined; 
overall and relapse-free survival in these patients was evaluated depending on the tumor HRS. Results: Positive expression of ER has 
been registered in 66.4% of patients with serous OC, PR — in 63.4%, TR — in 53.0%; in patients with mucinous OC — 88.0; 
84.0; 60.0%, respectively. Positive staining of cells of stroma-cellular tumors has been observed in 74.1% of patients for ER and 
77.8% — for PR and TR. The highest number of patients with tumor phenotype ER+PR+TR+ has been observed in postmeno-
pause — 52.4%, especially in late postmenopausal period — 39.0%. The lowest percentage of patients with mentioned phenotype 
has been marked in reproductive age — 20.7%. Most patients of reproductive period had phenotype of tumor ER-PR-TR- (35.1%), 
in late postmenopause this phenotype has been observed only in 16.2%. The patients with serous OC with the positive tumor HRS 
demonstrated the low indices of overall and relapse-free survival compared to the patients with receptor-negative tumors con cerning 
all steroid hormones (р < 0.05). Conclusions: Positive HRS was registered in serous, mucinous OC and in SCST, high percen tage 
of tumors with expression of all receptors of steroid hormones was observed at that. The highest frequency of tumors with positive 
HRS was recorded in patients with serous OC of late postmenopausal period. The patients with serous OC with receptor-positive 
tumor phenotype showed the rates of overall and relapse-free survival significantly lower compared to the patients with receptor-
negative phenotype of OC. Positive HRS, the same as strong expression of TR in patients with serous OC, is a predictive factor 
of unfavorable course of tumor process. HRS of MOT can be regarded as the additional criterion for solution of a question con-
cerning application of hormonal therapy as a component of complex treatment for the patients.
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Malignant ovarian tumors (MOT) are one of the most 
complicated problems in oncogynecology [1, 2]. 
Complexity of the problem lies in uniqueness of this 
organ and its role in a woman organism [3, 4]. Multi-
component structure of gonad, variety of structures with 
different functions provides a wide range of histological 
forms of ovarian tumors and complexity of etiopatho-
genesis of this disease [5]. Hormonal factors play 
the most important role in pathogenesis of MOT at pre-
sent time. Ceaseless ovulation owing to pregnancies 
and childbirths declination in some countries, sterility 
of different genesis and application of drugs stimulating 
ovulation belong to them [6–8]. According to the data 
of literature, ovaries are not only producing sex steroid 
hormones, but also act as a target tissue for them, 
the same as other hormone-dependent organs [9]. 
Estrogens, progesterone and testosterone, the same 
as receptors to them, are promoters of all hormone-
dependent tumors, in particular, of breast cancer (BC), 
endometrial and ovarian cancer (OC) [10].
Therapy strategy for patients with MOT includes 
surgical component and chemotherapy. Despite 
improvement of surgical treatment strategies and ap-
plication of modern chemotherapy schemes [2–14], 
long-term results of treatment in patients with dissemi-
nated MOT remain unsatisfactory [15, 16].
For many years, hormonal therapy for patients with 
progressing and chemo-resistant MOT has been em-
pirically prescribed as “despair therapy” demonstrating 
the low rate of efficacy [17]. Clinical interest in hormonal 
treatment of OC patients was increased due to de-
velopment of molecular-biological technologies and 
possibility to determine receptors to estrogens (ER), 
progesterone (PR) and androgens in tumor tissue [18]. 
However, criteria of hormone-dependency of MOT and 
application of hormonal therapy in combined treatment 
of patients, the same as prognosis depending on ex-
pression of steroid receptors are remaining disputable.
Prognostic value of hormonal receptor status (HRS) 
of MOT has been studied for many years. Certain 
studies have determined high survival of OC patients 
at expression of ER and PR in tumor [19–21]. Other 
studies shown that expression of PR and receptors 
to testosterone (TR) are favorable prognostic factors, 
and expression of ER is associated with progression 
of disease and short relapse-free period [22–26].
Interrelation between HRS and degree of tumor 
differentiation as well as impact of chemotherapy 
on ER, PR, TR in tumor tissue of ovary has not been 
determined yet [9, 27].
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Thus, the question concerning the mechanisms 
for realization of systemic-local dyshormonal disor-
ders causing MOT and clinical significance of ovarian 
tumors receptor status till this day remains open. 
Solution of this question will allow us to specify MOT 
pathogenesis, prognosis of disease, but also to sub-
stantiate indications for hormone therapy carrying out 
as a component of the patients’ combined treatment.
The aim of the research was to study HRS of MOT 
of different genesis and to determine its clinical sig-
nificance in patients with serous OC.
MATERIAL AND METHODS
The results of retrospective analysis of case his-
tories of 284 patients with MOT of different genesis 
of I–IV stages and paraffin blocks of postsurgical mate-
rial have been taken as material for study. Patients were 
treated in National Cancer Institute within 2001–2009. 
All patients underwent treatment by radical pro-
gram: surgical, combined and complex ( according 
to the standards of cancer patients’ diagnostics 
and treatment approved by orders of MH of Ukraine 
№ 140 from 27.07.1998 and № 554 from 17.09.2007). 
Combined treatment consisted in cytoreductive sur-
gery followed by adjuvant chemotherapy or in combi-
nation with neoadjuvant chemotherapy. Complex treat-
ment included surgical intervention, chemotherapy 
and radiation. Informed consent was received from all 
of the patients participating in the study.
MOT diagnosis has been verified using morpho-
logical study of post-surgical material  according 
to the histological classification of ovarian tu-
mors (2002), clinical staging of MOT — by international 
FIGO classification (2009) [28].
Immunohistochemical study of ER, PR, and 
TR in ovarian tumor cells has been carried out on paraf-
fin sections 4–5 micron thickness, which were placed 
on glasses processed with poly-L-lysine. As primary an-
tibodies, monoclonal antibodies specific to ER, PR and 
TR have been used (anti-Human Estrogen Receptor 
alfa Clone 1D5 (DakoCytomation, Denmark), anti-
Human Progesterone Receptor Clone PgR 636 (Dako-
Cytomation, Denmark), testosterone antibody Clone 
GTX72779 (GeneTex, USA)). For visu alization of the 
results of reaction, kit of reagents En Vision system 
(DakoLSAB2system, Denmark) has been used in ac-
cordance with recommendations of the manu facturer, 
sections were stained by Meyer’s hematoxylin. For 
evaluation of immunohistochemical expression of ER, 
PR and TR, semi-quantitative method has been ap-
plied. At presence of specific nuclear staining, the 
quantity of immune-positive and immune-negative 
cells in percentage has been determined. In each 
histological specimen, expression of steroid receptors 
in 1000 tumor cells has been analyzed. Since till this 
day no conventional semi-quantitative methods of to-
tal assessment of HRS for MOT exist, method, which 
is mostly found in data of literature [29], has been 
taken as a model. Degree of steroid receptor expres-
sion has been taken in scores: 0 scores — no staining 
of nuclei of tumor cells; 1 score — poor staining ≤ 10%; 
2 scores — moderate staining — 11–50%; 3 scores — 
high staining — 51–80%; 4 scores — hyperexpres-
sion — >81% of cells. The quantity of stained nuclei with 
more than 10% of moderate and high level of staining 
has been regarded as a positive expression of steroid 
receptors. As positive control, monoclonal antibodies 
against pan-cytokeratins have been used; as negative 
control — buffered physiological solution has been 
applied to histological sections, instead of monoclonal 
antibodies.
Results of studies have been evaluated depending 
on women age periods: reproductive (up to 45), peri-
menopause (46–55), early postmenopause (56–60) 
and late postmenopause (61 and more) according 
to the WHO classification (1980) [30]. Overall and 
relapse-free survival of patients with serous OC de-
pending on tumor HRS has been determined. Corre-
lation between HRS and stage, tumor differentiation 
grade has been assessed. Influence of neoadjuvant 
chemotherapy on expression of steroid hormone re-
ceptors in serous OC has been analyzed.
Statistical analysis of obtained data consisted 
in use of nonparametric statistics. For comparison 
of studied groups, U-criterion of Whitney — Mann has 
been applied. Correlation has been evaluated using 
Gamma rank correlation. Survival of patient has been 
analyzed by Kaplan — Meier method and log-rank 
criterion. Statistically significant were considered data 
at р < 0.05. Processing of results of study has been 
carried out using program package STATISTICA 6.0.
RESULTS AND DISCUSSION
Analysis of case histories has demonstrated 
that age of patients with MOT (n = 284) of different 
genesis varied from 16 to 82, mean age 52.8 ± 2.2. 
By histological structure of tumors, patients were 
allocated (Table 1) into serous OC (232/81.7%), 
mucinous OC (25/8.8%), sex cord-stromal tu-
mors (SCST) (27/9.5%). Mean age of patients was 
equal (51.7, 52.8 and 53.9, respectively).
Table 1. Distribution of patients by age, MOT histology, grade of tumor 
differentiation (n = 284)
Histological 
type of tu-
mor
Number 
of patients Mean age/range, years
Tumor differentiation grade
high moderate low
n % n % n % n %
Serous OC 232 100.0 51.7±0.8/18–82 45 19.4 73 31.5 114 49.1
Mucinous OC 25 100.0 52.8±3.2/16–69 7 28.0 10 40.0 8 32.0
SCST 27 100.0 53.9±2.5/27–70 3 11.1 8 29.6 16 59.3
Patients with MOT, who were prescribed neoad-
juvant chemotherapy, depending on genesis of tu-
mors, have been divided as follows: serous OC has 
been diagnosed in 84 (36.2%) patients, mucinous 
OC — in 2 (7.4%) and SCST — in 4 (16.0%). Grade 
of differentiation of ovarian tumors is represented 
in Table 1. Patients with serous OC and SCST had high 
percentage of tumors with low differentiation (49.1 and 
59.3%, respectively). In patients with mucinous OC, 
most tumors were moderately differentiated (40.0%).
Analysis of MOT spreading has showed that 
number of patients with III stage was the  highest — 
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73.6% (n = 209). Data on distribution of patients by sta-
ges depending on histological MOT type are repre-
sented in Table 2. As seen from Table 2, expression 
of steroid hormones in MOT was variable. Positive 
expression of ER was observed in 66.4% of patients with 
serous OC, PR — in 63.4%, TR — in 53.0% (Fig. 1–3 and 
see Table 2). 
a
b
c
Fig. 1. Serous OC. Immunohistochemical expression of ER in tu-
mor cells (× 400): a — no expression; b — low expression of ER; 
c — high expression of ER
Positive expression of the same markers has been 
detected in patients with mucinous OC — 88.0; 84.0; 
60.0%, respectively. Positive staining of cells of stroma-
cell tumors has been observed in 74.1% of patients for 
ER and 77.8% — for RP and TR. It should be mentioned 
that the highest percentage of receptor-positive tumors 
has been determined in patients with mucinous OC and 
SCST. Statistical analysis has demonstrated significant 
rank correlation between morphological structure of tu-
mors and expression of steroid hormone receptors: for 
ER — r = 0.364 (р = 0.002), RP — r = 0.408 (р < 0.001) 
and TR — r = 0.289 (р = 0.0048) (Table 3). When com-
paring frequencies of expression of steroid hormone 
receptors in serous OC and SCST, reliable differences 
have been established only for TR (р = 0.016). When 
comparing frequency of expression of steroid hormone 
receptors in serous and mucinous OC, differences for 
ER and PR have been marked (р = 0.027 and р = 0.039, 
respectively), but when comparing frequencies of ex-
pression of ER, PR and TR in mucinous OC and SCST, 
no significant differences were found.
a
b
Fig. 2. Serous OC. Immunohistochemical expression of PR in tumor 
cells (× 400): a — low expression of PR; b — high expression of PR
Table 2. Frequency of receptor-positive MOT of different genesis de-
pending on stage of disease (by ER, PR and TR) (n = 284)
Number of patients with receptor-positive tumor
MOT histology/stages ER + PR + TR +n % n % n %
Serous OC
n = 232 (100.0%)
154 66.4 147 63.4 123 53.0
I stage, n = 23 (100.0%) 20 87.0 17 73.9 13 56.5
II stage, n = 13 (100.0%) 11 84.6 11 84.6 2 15.4
III stage, n = 185 (100.0%) 116 62.7 113 61.1 103 55.7
IV stage, n = 11 (100.0%) 7 63.6 6 54.5 5 45.5
Mucinous OC, n = 25 (100.0%) 22 88.0 21 84.0 15 60.0
I–II stage, n = 10 (100.0%) 9 90.0 8 80.0 6 60.0
III stage, n = 15 (100.0%) 13 86.7 13 86.7 9 60.0
SCST n = 27 (100.0%) 20 74.1 21 77.8 21 77.8
I–II stage, n = 17 (100.0%) 11 64.7 11 64.7 15 88.2
III stage, n = 10 (100.0%) 9 90.0 10 100.0 6 60.0
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a
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Fig. 3. Serous OC. Immunohistochemical expression of TR in tumor 
cells (× 400): a — low expression of TR; b — high expression of TR
Table 3. Gamma rank correlations between steroid hormone receptors, 
phenotype of tumor, its grade of differentiation, stage of disease, neoadju-
vant chemotherapy, age period of patients with serous OC (n = 232)
Rate Correlation coefficient p
ER & stage −0.420 0.0005
ER & tumor differentiation grade −0.118 0.1470
ER & neoadjuvant chemotherapy −0.154 0.1056
ER & PR 0.913 0.0001
ER & TR 0.362 0.0001
ER & age period −0.253 0.0009
PR & stage −0.310 0.0062
PR & tumor differentiation grade −0.060 0.4565
PR & neoadjuvant chemotherapy −0.316 0.0005
PR & ER 0.913 0.0001
PR & TR 0.374 0.0001
PR & age period −0.173 0.0205
TR & stage 0.176 0.0902
TR & tumor differentiation grade 0.045 0.5632
TR & neoadjuvant chemotherapy 0.041 0.6528
TR & ER 0.362 0.0001
TR & PR 0.374 0.0001
TR & age period −0.076 0.2968
Tumor phenotype & stage 0.118 0.1531
Tumor phenotype & tumor differentiation grade 0.031 0.6120
Tumor phenotype & neoadjuvant chemotherapy 0.117 0.1063
Tumor phenotype & age period 0.180 0.0017
Weak correlation between frequency of expression 
of ER, PR in tumors of different genesis and stage 
of dise ase has been established: r = −0.304 (р = 0.002) 
and r = −0.207 (р = 0.027), respectively (see Table 2, 
 Table 4). In patients with serous OC, at increase of dise-
ase stage, tendency to decline of expression frequency 
for ER and PR has been determined, while in patients 
with mucinous OC and SCST, tendency to ele vation 
of expression frequency for these receptors has been 
observed. No connection between TR expression in tu-
mors of different genesis and stage of tumor process 
has been noticed (r = −0.053, р = 0.538).
Table 4. Gamma rank correlations between expression of steroid hormone 
receptors, histological type and tumor differentiation grade, stage of dise-
ase in patients with MOT (n = 284)
Index Stage
Histo-
lo gical 
type 
of tumor
Diffe-
rentiation 
of tumor
ER PR TR
Stage 1.000 −0.587* 0.128 −0.304* −0.207* −0.053
Histological 
type of tumor
−0.587* 1.000 −0.069 0.364* 0.408* 0.289*
Differentiation 
of tumor
0.128 −0.069 1.000 −0.066 0.020 0.054
ER −0.304* 0.364* −0.066 1.000 0.928* 0.398*
PR −0.207* 0.408* 0.020 0.928* 1.000 0.354*
TR −0.053 0.289* 0.054 0.398* 0.354* 1.000
Notes: *correlation coefficient significant at the level of р < 0.05.
Statistical analysis has not detected significant cor-
relation between frequency of receptor-positive MOT 
of different genesis (see Table 4) and grade of MOT 
differentiation: for ER — р = 0.382, PR — р = 0.789 and 
TR– р = 0.444. However, significant correlation of influ-
ence of chemotherapy on expression of PR (p = 0.001) 
and lack of influence on expression of ER and TR 
(р = 0.091 and р = 0.787, respectively) has been 
determined. When analyzing dependence of expres-
sion of steroid receptors between each other, rank 
correlation between ER and PR (р < 0.0001), ER and 
TR (р < 0.001), PR and TR (р < 0.001) was reported, 
it was especially significant between ER and PR with 
r = 0.928.
Thus, positive HRS was found not only in serous, 
but also in mucinous OC and SCST, the highest 
percentage of receptor-positive tumors at that was 
determined in patients with mucinous OC, which 
is characterized by unfavorable clinical course of tumor 
process, and in patients with SCST, which are known 
to have high hormonal activity [2, 31]. It was confirmed 
by the determined correlation between morphological 
structure of tumors and expression of steroid hormone 
receptors. Represented results have showed that 
ovary with malignant tumor of different histogenesis 
is a target tissue for systemic-local classic and non-
classic steroids independently of grade of differentia-
tion of tumor tissue.
Most numerous group in our study consisted of pa-
tients with serous OC (n = 232), therefore, the further 
analysis has been carried out for these category of pa-
tients. Mean period of observation of patients with serous 
OC was 39.5 ± 1.7 months, mean relapse-free period — 
33.7 ± 1.8 months, median of relapse-free survival — 
30.0 ± 2.1 months. Out of total number of patients, 28.4% 
were in reproductive period, 31.0% — in perimenopausal 
and 40.5% — in postmenopausal period (in early post-
menopausal — 15.1%, in late menopausal — 25.4%). 
In 149 (64.2%) patients, the relapse of disease has been 
determined. Patients with relapse of disease depending 
on age period have been divided as follows: 30 (20.1%) 
patients of reproductive period, 55 (36.9%) — perimeno-
pause, number of patients of postmenopausal period was 
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the highest — 64 (42.0%), among them — 22 (14.8%) 
patients in early menopause, and 42 (28.2%) — late 
postmenopause. It should be mentioned that the highest 
number of relapses in patients with OC has been observed 
in perimenopause and in postmenopause that indicates 
most aggressive course of disease and unfavorable 
prognosis.
When analyzing expression of steroid hormone 
receptors in serous OC depending on age of pa-
tients (Table 5), we have noticed that mostly estrogen-, 
progesterone-, testosterone-receptor-positive tumors 
have been observed in late postmenopause — 79.7%, 
79.7 and 59.3%, respectively. Significant rank correla-
tion (see Table 3) between frequency of expression 
of ER, PR and age of patients has been established 
(r = −0.253 at р < 0.001 and r = −0.173 at р = 0.021, 
respectively). Correlation coefficient for TR composed 
−0.076 at р = 0.297 (see Table 3) that is the evidence 
of absence of correlation of this factor with age of pa-
tients. Second place by frequency of receptor-positive 
tumors belongs to the patients of perimenopausal age. 
As it has been determined earlier, patients with serous 
OC in the exactly perimenopausal and postmenopausal 
periods have most aggressive course and unfavorable 
prognosis of disease [4, 5, 9]. In postmenopausal peri-
od taken as a whole, ER at serous OC has been detected 
in 70.2% of patients, PR — in 73.4%, and TR — in 54.3%. 
The lowest percentage of receptor-positive tumors has 
been observed in patients of reproductive age.
Table 5. Frequency of ER, PR and TR in patients with serous OC de-
pending on age period (n = 232)
Age period
Number of patients with receptor-positive tumor
ER + PR + TR + Total
n % n % n % n %
Reproductive period 42 63.6 35 53.0 32 48.5 66 100.0
Perimenopause 46 63.9 43 59.7 41 56.9 72 100.0
Postmenopause 66 70.2 69 73.4 51 54.3 94 100.0
Early postmenopause 19 54.3 22 62.9 16 45.7 35 100.0
Late postmenopause 47 79.7 47 79.7 35 59.3 59 100.0
Total 154 147 124 232
As seen in Table 3, there is no rank correlation between 
frequency of expression of steroid hormone receptors 
and grade of differentiation of tumors. However, it has 
been determined that neoadjuvant chemotherapy influ-
ences only PR expression (р = 0.0005), but, at the same 
time, has no influence on the concentration of ER and 
TR (р = 0.1056 and р = 0.6528, respectively). In serous 
OC, the same as in all MOT, we have registered sig-
nificant correlation between expression of ER and PR 
(r = 0.913 at р < 0.0001), ER and TR (r = 0.362 at р < 0.0001), 
PR and TR (r = 0.374 at р < 0.0001).
As seen in Table 6, the highest number of patients 
with serous OC had tumor phenotype, which was 
positive by all steroid hormone receptors (82/35.3%). 
Second place by frequency was taken by group of pa-
tients with tumor phenotype, which was positive only 
by ER and PR (49/21.1%). Third and fourth places 
belong to the patients with negative tumor phenotype 
by all receptors (37/15.9%) and phenotype, which was 
positive only by TR (25/10.8%). The fact was of inte-
rest that the highest number of patients with tumor 
phenotype ER+PR+TR+ has been observed in late post-
menopause — 39.0%, and in postmenopausal period 
taken as a whole, number of patients with such tumor 
phenotype has been constituted 43 (52.4%). The lo-
west percentage of patients with mentioned phenotype 
has been registered in reproductive age — 20.7%. 
Tumor phenotype ER+PR+TR− was in equal number 
of patients in postmenopausal and in reproductive 
period by 17 (34.7%) and only in perimenopause such 
tumor phenotype has been detected in 15 (30.6%) pa-
tients. It should be mentioned that the highest number 
of patients of reproductive age had tumor phenotype 
ER-PR-TR− (13/35.1%), and in late postmenopause 
this phenotype has been observed only in 16.2% of pa-
tients. When comparing patients of reproductive and 
late postmenopausal periods, significant differences 
for the phenotype of serous OC (р = 0.004) have been 
determined, such significant differences have been 
detected between patients in perimenopause and late 
postmenopause (р = 0.009). When comparing tumor 
phenotype of patients of reproductive, perimenopausal 
and early postmenopausal periods, no significant diffe-
rences were found (р = 0.850 and р = 0.873, respective-
ly). Also, there are no significant differences by tumor 
phenotype between patients of perimenopause and 
early postmenopause (р = 0.739).
Table 6. Distribution of patients with serous OC by tumor phenotype and 
age period (n = 232)
Tumor pheno-
type
Number of pa-
tients
Age periods
Repro-
ductive
Peri-
meno-
pause
Ear-
ly post-
meno-
pause
Late 
post-
meno-
pause
n (%) % n % n % n % n %
ER+PR+TR+ 82 (35.3) 100.0 17 20.7 22 26.9 11 13.4 32 39.0
ER+PR+TR– 49 (21.1) 100.0 17 34.7 15 30.6 6 12.2 11 22.5
ER+PR–TR+ 10 (4.3) 100.0 5 50.0 4 40.0 0 0.0 1 10.0
ER+PR–TR– 13 (5.6) 100.0 3 23.1 5 38.5 2 15.4 3 23.1
ER–PR+TR+ 7 (3.0) 100.0 0 0.0 5 71.4 2 28.6 0 0.0
ER–PR+TR– 9 (3.9) 100.0 1 11.1 1 11.1 3 33.3 4 44.4
ER–PR–TR+ 25 (10.8) 100.0 10 40.0 10 40.0 3 12.0 2 8.0
ER–PR–TR– 37 (15.9) 100.0 13 35.1 10 27.0 8 21.6 6 16.2
Total 232 (100.0) n = 66 n = 72 n = 35 n = 59
We have carried out univariate analysis of overall 
and relapse-free survivals of patients with serous 
OC depending on expression of each steroid hormone 
receptor (Fig. 4–9). Rates of overall and relapse-free 
survivals of patients are represented in Table 7. Data 
in Table 7 demonstrate that 3-year survival rate in pa-
tients with serous receptor-negative tumor to estrogens 
and progesterone was higher, than in patients with 
receptor-positive tumor, but diffe rences between them 
were insignificant (р = 0.594 and р = 0.452, respec-
tively), since 5-year survival rate in two groups of pa-
tients turned out to be the same and equaled 39.3%. 
Results of 3- and 5-year survi vals in patients with 
receptor-negative tumor to testosterone (see Fig. 6, 
Table 7) were interesting. They turned out to be sig-
nificantly higher, than in patients with receptor-positive 
tumors (р = 0.0345). It should be mentioned that median 
of relapse-free survival in patients with receptor-negative 
tumor concerning all steroid hormones was higher, than 
in patients with receptor-positive tumors, but significant 
rate has been determined only for TR (р < 0.0500).
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Fig. 4. Overall survival of patients with serous OC with expression 
of estrogen receptors Kaplan— Meier survival curves, log-rank 
criterion; р = 0.594
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Fig. 5. Overall survival of patients with serous OC with expres-
sion of progesterone receptor. Kaplan — Meier survival curves, 
log-rank criterion; р = 0.452
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Fig. 6. Overall survival of patients with serous OC with expres-
sion of testosterone receptor. Kaplan — Meier survival curves, 
log-rank criterion; р = 0.0345
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Fig. 7. Relapse-free survival of patients with serous OC with ex-
pression of estrogens receptor. Kaplan — Meier survival curves, 
log-rank criterion; р = 0.6876
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Fig. 8. Relapse-free survival of patients with serous OC with 
expression of progesterone receptor. Kaplan — Meier survival 
curves, log-rank criterion; р = 0,9534
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Fig. 9. Relapse-free survival of patients with serous OC with 
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Table 7. Overall and relapse-free survival in patients with serous OC de-
pending on expression of steroid hormone receptors
Steroid 
hormone 
receptors
Overall survival, % Median of relapse-free survival, months
Serous OC R+ Serous OC R– Serous 
OC R+
Serous 
OC R–3-year 5-year 3-year 5-year
ER 48.2±4.2 39.3±4.4 63.4±5.7 39.3±6.4 26.9±2.3 34.8±2.7
PR 49.7±4.3 39.3±4.4 60.0±5.5 39.3±6.1 27.8±2.4 32.0±2.5
TR 45.7±4.7 31.4±4.8 62.2±4.8 47.9±5.3 27.7±2.2 35.7±2.8
Notes: Serous OC R+ — receptor-positive serous OC; Serous OC R— — re-
ceptor-negative serous OC
Hereafter, differences in 3- and 5-year overall sur-
vival of patients with serous OC depending on tumor 
phenotype have been analyzed (Fig. 10). Statistically 
significant intergroup differences in survival of patients 
with the following phenotypes have been determined: 
ER+PR+TR+ and ER−PR−TR− (р = 0.006), between 
ER+PR+TR+ and ER+PR+TR– (р = 0.0150), between 
ER+PR+TR+ and ER–PR–TR+ (р < 0.050). For this 
reason, we have evaluated survival of patients, who 
had above-listed phenotypes of serous OC only. Pa-
tients with tumor phenotype, which was negative by all 
steroid hormone receptors, had higher 3- and 5-year 
survival rates, than patients, who had positive HRS 
of tumor: 67.8/44.5% and 39.9/29.5%, respectively. 
In patients with tumor phenotype ER+PR+TR–, rates 
of 3- and 5-year survival have constituted 60.5/49.2% 
compared to 39.9/29.5% — rates of overall survival 
of patients with positive HRS OC. However, in group 
of patients with phenotype tumor, which was positive 
only by TR, high survival rates have also been recorded 
(60.5/49.5%) compared to the same in OC patients, 
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which was a positive tumor by all steroid hormone 
receptors (39.9/29.5%). Thus, the lowest survival 
rates have been observed in patients, who had posi-
tive HRS tumors.
When evaluating relapse-free survival of patients 
depending on serous OC phenotype (Fig. 11), sig-
nificant intergroup differences only for tumors with 
phenotypes ER+PR+TR+ and ER+PR+TR− have been 
obtained (р < 0.050). The highest rate of relapse-
free survival has been determined in patients with 
ER+PR+TR− OC phenotype (50.8/43.3%) if com-
pared with survival of the patients, who had positive 
HRS (33.5/25.5%), the absence of TR expression play 
the key role.
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Fig. 10. Overall survival of patients with serous OC depending 
on tumor phenotype. *p < 0.05 if 3-year and 5-year groups are 
compared
16
,922
,7
32
,1
33
,5
35
,6
40
,5
46
,150
,8
41
,2
14
,5
20
,3
25
,5
20
,2
18
,023
,7
43
,3
33
,8
0
10
20
30
40
50
60
70
W
ho
le
 g
ro
up
ER
+P
R+
TR
-
ER
-P
R-
TR
-
ER
-P
R+
TR
-
ER
-P
R-
TR
+
ER
+P
R+
TR
+
ER
+P
R-
TR
-
ER
-P
R+
TR
+
ER
+P
R-
TR
+
Su
rv
iva
l, 
%
3-year
5-year
*
*
*
*
Fig. 11. Relapse-free survival of patients with serous OC de-
pending on tumor phenotype. *p < 0.05 if 3-year and 5-year 
groups are compared
Represented results have demonstrated sig-
nificant correlation between ER, PR, and TR in MOT 
that corresponds to data of some studies carried 
out before [31]. It is known that steroid hormones 
are able to regulate the level of not only own recep-
tors, but also to modulate content of receptors of the 
other hormones. For instance, estradiol stimulates 
the formation of PR, while progesterone decreases 
expression of ER in reproductive organs. Moreover, 
estradiol is able to increase level of ovarian androgenic 
receptors several times [32].
The highest frequency of receptor-positive tumors 
has been observed in patients with serous OC of post-
menopausal period, which, by own observations and 
data of literature, is characterized by aggressive course 
and unfavorable prognosis of disease [2]. Such simila-
rity by clinical course and tumor HRS is being detected 
also in patients with BC of postmenopausal period, but, 
at luminal A type of tumor in BC patients, the favorable 
prognosis of disease is being predicted [33]. Thus, 
the highest number of patients with serous OC with posi-
tive HRS has been observed in late postmenopausal 
period. It is the evidence of possible high sensitivity 
of tumor cells of patients of this age category to the im-
pact of steroid hormones, most of which are formed 
due to extragonadal aromatization of androgens [6].
Univariate analysis has showed that overall and 
relapse-free survivals are higher in patients with 
receptor-negative tumor by ER, PR and TR, than with 
receptor-positive tumors, but significant differences 
have been registered only for TR.
Represented results have demonstrated low overall 
and relapse-free survivals in patients with OС phe-
notype, which was receptor-positive for all steroid 
hormones. The highest rates of overall 5-year survival 
have been determined in patients with not only tumor 
phenotype ER–PR–TR–, but also with ER+PR+TR–. 
Relapse-free survival also was the highest in patients 
with serous OC phenotype ER+PR+TR– that indicates 
certain role of TR in clinical course of tumor process.
Obtained results, on the one hand, corresponds 
to the data of some studies, which have demonstrated 
that strong expression of androgen receptors is being 
observed in case of invasive OC, and hyperandrogenia 
can be a risk factor of occurrence and progression of this 
disease [34]. On the other hand, results of our study con-
tradict the data of other studies, which have determined 
that high expression of androgen receptors is a favorable 
prognostic factor in patients with serous OC [35].
Today it is known that androgens, when interacting 
with receptors, cause strong proliferative processes 
in ovarian tissue (hyperplasia of stroma, thecal tissue 
and cells of hilum of ovary) at endocrine syndromes 
of reproductive system, in particular, polycystic 
ovary syndrome. Moreover, level of androgens and 
expression of receptors at these syndromes are able 
to increase synchronously with a lapse of time [36]. 
Postmenopausal ovary is androgenic ovary, which 
stroma is the only source of gonadal hormone repro-
duction in this age period. It has been proved that con-
centration of testosterone in ovarian vein is 15 times 
higher, than level of the last one in blood serum from 
peripheral vein [37]. As it has been stated above, pe-
ripheral synthesis of non-classic estrogens (phenol 
steroids) becomes more intensive in postmenopause. 
These estrogens possess weaker inhibi ting effect 
on hypothalamus-hypophysis system, than classic 
estrogens [6], and increase of gonadotropins produc-
tion stipulates hyperplasia of ovarian thecal tissue that, 
in turn, can intensify synthesis of androgens [30, 36]. 
Non-classic phenol steroids and estrone are main hor-
mones in postmenopause. They are formed as the re-
sult of aromatization from androstenedione, secretion 
of which in menopause is provided mostly by adrenal 
glands and less — by ovaries [30, 36]. Phenol ste-
roids are strong agonists of estradiol, acti vity of these 
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 metabolites increases activity of the latter in several 
times (in particular, 16-α-hydroxyestrone 1 in 8 times), 
they form stable connections with specific receptors 
of cells of different tissues [38, 39].
It has been proved that transformation of androstene-
dione in estrone in percentage correlates with weight 
of women. Entering of estrogens through aromatization 
of androgens is not limited only by fat tissue — almost 
all tissues of organism have this property. ER (α and β) 
are found in brain, blood vessels, heart, bones, mam-
mary glands, uterus, ovaries. ER-β were detected only 
in lungs, kidneys, urinary bladder, intestine. Extragonadal 
estrogen- and androgen-formation serves as source 
of additional hormonal stimulation [6, 36, 38, 39].
Among age endocrine-metabolic changes in wo-
men, which are manifested by obesity and insulin-resis-
tance, compensatory hyperinsulinemia arises [7]. Insu-
lin indirectly, via receptors of insulin-like growth factor I, 
the same as luteinizing hormone, intensifies enzyme 
activity of biosynthesis of androgens in ovaries that 
causes certain increase of their functions [36]. It has 
been proved for today that androgen-regulating genes 
stimulate expression of epidermal growth factor, vas-
cular endothelial growth factor and cyclin-dependent 
kinases 2 and 4. At the same time, they have repressing 
effect on the expression of TGF-β and Bcl-2 [32].
In postmenopause, along with switching off of ovu-
latory function of ovaries, takes place strong switching 
on of series of compensatory mechanisms providing 
sufficient level and wide range of biologically active me-
tabolites, and at certain factors there are all necessary 
conditions for stimulation of target organs by them [6].
Thus, obtained results have demonstrated that 
endocrine factors and hormonal-receptor changes 
in ovaries is a considerable element of not only 
pathogenesis, but also important prognostic criterion 
in postmenopausal patients with MOT. It represents 
integral part of general mechanism of complicated 
molecular-genetic interactions.
In conclusion, positive HRS has been determined 
in serous, mucinous OC and in SCST. High percentage 
of tumors with the expression of all steroid hormone 
receptors has been observed in them. However, 
the highest percentage of receptor-positive tumors 
has been detected in patients with mucinous OC and 
SCST that is confirmed by established correlation 
between morphological structure of tumors and ex-
pression of steroid hormone receptors.
Weak correlation between frequency of expression 
of ER, PR and lack of such expression between expres-
sions of TR in tumors of different genesis and stage 
of disease has been established. Expression of steroid 
hormone receptors does not depend on grade of dif-
ferentiation of tumor tissue.
In patients with serous OC of late menopausal pe-
riod, the highest frequency of tumors with positive HRS 
is registered that allows to assume that there is a high 
sensitivity of these tumors both to endogenous ste-
roids and hormonal therapy.
In patients with serous OC with receptor-positive 
tumor phenotype, rates of overall and relapse-free sur-
vivals are significantly lower compared to the patients 
with receptor-negative OC phenotype.
Positive HRS, the same as strong expression 
of TR in patients with serous OC, is a predictive factor 
of unfavorable course of tumor process.
HRS of MOT can be regarded as the additional 
criterion for solution of a question concerning applica-
tion of hormonal therapy as a component of complex 
treatment for the patients that needs further large 
multi-center studies in this direction.
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